Conference abstract · 2019
EditorialPublished 2021
Pseudoprogression under checkpoint inhibition therapy
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
A novel agent called checkpoint inhibitor therapy has revolutionized not only the treatment for several tumor entities but also our general understanding of oncology. As more and more patients with solid tumors undergo this promising immune therapy, new phenomena like pseudoprogression challenge the clinician. Pseudoprogression is a temporary increase in tumor size due to infiltrating leucocytes and edema during checkpoint inhibitor therapy, which can be mistaken with real progression. Subsequently, tumor size decreases due to tumor cell destruction. Pseudoprogression is described in 1,5% - 17% of all cases - depending on the tumor entity and study. Identifying pseudoprogression plays a decisive part in successfully using checkpoint inhibition therapy, because the misinterpretation of tumor growth might lead to the discontinuation of an effective treatment, as pseudoprogression indicates a high likelihood of > 1year survival. In order to guarantee the best possible treatment, it is crucial to be informed about pseudoprogression and to know techniques to distinguish between pseudo- and real progression when tumor size increases under checkpoint inhibition therapy. While there are several indicators to differentiate between the two, ultimately only infiltrating growth – which solely occurs in malign tumor growth – proves real progression.
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Commentary · 6 Jun 2025
Synergistic Effect of Photothermal Therapy and Immune Checkpoint Inhibition
Research article · 22 Sep 2020
A Phase I Study of Immune Checkpoint Inhibition (anti- CTLA4 and anti-PD-L1) in Combination with Radiation Therapy in Patients with Locally Advanced Unresectable Pancreatic Cancer
Mini review · 2017
Cancer Genomics in the Era of Checkpoint Inhibition: Biomarkers to Predict Tumor Response to Checkpoint Inhibition Therapy
Conference abstract
Engineered erythrocytes as an anti-tumor therapy through induction of apoptosis or immune-checkpoint inhibition
More from this journal
The newest in Acta Psychopathologica.
Article · 24 Feb 2025
Investigating the Linkage of Anxiety and Depression to the Feeling of Anguish
Article · 17 Jan 2025
Cognitive Behavioral Therapy for Treating Complex Anxiety Disorders in Adolescent Populations: A Comprehensive Systematic Review and Meta-Analysis
Article · 30 Dec 2024
Mental Health Disorders in the Digital Age: Challenges and Solutions
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalActa Psychopathologica
- BylineArticles whose byline prints “Mona Passler Department of Gynecology”
- BylineArticles whose byline prints “Competence Center for Ovarian Cancer (EKZE)”
- BylineArticles whose byline prints “Charité - University Medicine”
- BylineArticles whose byline prints “Berlin”
- BylineArticles whose byline prints “Germany”
